morningstar.com
Cure8 news brief
Why This Matters
Researchers and clinicians are watching new oral therapies for patients whose disease has failed biologic treatments. If supported by full data, a safe, oral drug that helps refractory Crohn’s disease and ulcerative colitis and can be continued during C.
difficile infection would be important for people with hard-to-treat IBD.
Who Should Pay Attention
Patients with refractory IBD or prior biologic failure, clinicians treating difficult-to-treat Crohn’s disease or ulcerative colitis, and researchers interested in immunometabolism and LANCL2-targeted drug development.
Study Snapshot
Story typeBusiness news
Evidence typeConference abstract
Source depthFull source text
What To Know
NImmune Biopharma will present two abstracts at ACG 2026 on NIM-1324, an oral, once-daily LANCL2-targeting medicine being developed for ulcerative colitis and Crohn’s disease.
The company says the presentations include clinical and preclinical data suggesting NIM-1324 may help patients with biologic-refractory IBD and could reduce severity and recurrence of Clostridioides difficile when it co-occurs with IBD. The announcement is a company press release summarizing planned conference presentations rather than a peer-reviewed paper.
The company emphasizes NIM-1324’s dual immunometabolic mechanism (activation of regulatory T cells and enhancement of mitochondrial metabolism) as the rationale for potential benefits in hard-to-treat IBD. The release also states the data will be presented on October 11, 2026 at ACG 2026.
This is early-stage/clinical-development news about a proprietary drug and mechanism; it reports planned conference presentations and company interpretation of the data rather than providing full study methods or results. Look for the actual ACG abstracts or subsequent peer-reviewed publications for detailed evidence.
Keep In Mind
This is a company press release about planned conference presentations (ACG 2026). It summarizes the company’s interpretation of clinical and preclinical data but does not include full methods or results. Conference abstracts and peer-reviewed publications will be needed to evaluate safety and efficacy claims.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmorningstar.com
Indexed viaGoogle News
Source typeWeb article
PublishedSep 14, 2026, 12:12 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026
This announcement signals growing clinical and preclinical data for obefazimod, an investigational IBD drug; it includes a preclinical report on anti-fibrotic activity, a complication important in Crohn’s disease.